SCHEMBL5134629

SCHEMBL5134629

CCCCn1c(CN(Cc2ccc(SC)cc2)Cc2ccc3c(c2)OCO3)cnc1-c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
F2R P25116 2/20 0.41
HSP90AA1 P07900 2/20 0.38
HSP90AB1 P08238 2/20 0.38
CTSL P07711 3/20 0.37
PDE5A O76074 3/20 0.37
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.36
PKM P14618 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TDP1 Q9NUW8 1/20 0.35
UBE2M P61081 1/20 0.35
DCUN1D1 Q96GG9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136695 0.94 C5AR1 (0.43) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL4766728 0.93 C5AR1 (0.51) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL5136453 0.92 C5AR1 (0.55) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL5135741 0.92 C5AR1 (0.48) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL5135932 0.91 C5AR1 (0.46) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL5147409 0.91 C5AR1 (0.54) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL5137625 0.90 C5AR1 (0.47) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL5135991 0.90 C5AR1 (0.56) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL5136147 0.89 C5AR1 (0.47) C5AR1F2RHSP90AA1HSP90AB1CTSL
SCHEMBL5149996 0.89 C5AR1 (0.49) C5AR1F2RHSP90AA1HSP90AB1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed